Alpha1-proteinase inhibitor deficiency research hub

A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency

This study looks at a medicine called Respreeza to see how well it helps adults with a lung condition called emphysema caused by Alpha-1 Antitrypsin Deficiency. It checks if the medicine improves breathing and is safe when given weekly for three years.